AIBT · XBRL financial data
Aibotics financial statements, every fiscal year
The same tables from 10 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (AIBT's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | 0 | 2 |
| Gross profit | — | — | — | — | 0 | 2 |
| General and administrative | 14 | 4,987 | 1,736 | 617 | 1,635 | 1,847 |
| Total operating expenses | 14 | 4,987 | 1,736 | 617 | 1,635 | 1,847 |
| Operating income (loss) | (14) | (4,987) | (1,736) | (617) | (1,635) | (1,845) |
| Interest expense | 0 | 143 | 868 | 565 | 213 | 227 |
| Income tax expense (benefit) | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income (loss) | (16) | (5,139) | (2,612) | (1,181) | (1,848) | (2,216) |
- † Share count changed about 13x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (AIBT's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 57 | 1,268 | 386 | 279 | 185 | 256 |
| Inventory | — | — | — | — | — | 0 |
| Total current assets | 455 | 1,268 | 386 | 279 | 185 | 270 |
| Property and equipment, net | 0 | 2 | 1 | 0 | 0 | 0 |
| Total assets | 455 | 1,270 | 387 | 2,219 | 1,457 | 875 |
| Accounts payable | 0 | 121 | — | — | — | — |
| Accrued liabilities | 1 | 10 | 0 | 240 | 400 | 217 |
| Total current liabilities | 1 | 594 | 765 | 4,248 | 4,852 | 4,794 |
| Total liabilities | 1 | 1,218 | 1,279 | 4,248 | 4,852 | 4,835 |
| Retained earnings (accumulated deficit) | 371 | (5,168) | (7,780) | (8,961) | (10,809) | (13,025) |
| Total stockholders' equity | 454 | 52 | (891) | (2,028) | (3,395) | (3,960) |
| Total liabilities and equity | 455 | 1,270 | 387 | 2,219 | 1,457 | 875 |
| Common shares outstanding (cover page) thousands of shares | 12,925 | 14,322 | 14,858 | 14,897 | 42,691 | 567,695 |
- † Share count changed about 13x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (AIBT's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (16) | (5,139) | (2,612) | (1,181) | (1,848) | (2,216) |
| Stock-based compensation | (20) | 4,312 | 1,023 | 1 | 0 | — |
| Net cash from operating activities | (303) | (235) | (657) | (107) | (259) | (458) |
| Purchases of property and equipment | 0 | 3 | 0 | — | — | — |
| Net cash from investing activities | (349) | (3) | 0 | 0 | — | — |
| Proceeds from issuing common stock | — | — | — | — | 0 | 279 |
| Net cash from financing activities | 125 | 1,395 | (225) | 0 | 165 | 529 |
| Net change in cash | 111 | 1,157 | (882) | — | — | — |
- † Share count changed about 13x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Aibotics | 233 | 0 | (47)* | 850.2M | 5.0 quarters | 10-QJun 30, 2026 |
| Agentix | 0 | not reported | (26) | 40.1M | 0.0 quarters | 10-QJun 30, 2026 |
| Galera Therapeutics | 5,500 | not reported | (875) | 160.4M | 6.3 quarters | 10-QMar 31, 2026 |
| ProtoKinetix | 1.1 | not reported | 0.6* | 411.6M | — | 10-KDec 31, 2025 |
| Evofem Biosciences | 285 | 2,633 | (3,140)* | 132.5M | 0.1 quarters | 10-QJun 30, 2026 |
| Regen BioPharma | 0.2 | 59 | (24)* | 1.7B | 0.0 quarters | 10-QJun 30, 2026 |
| Twinlab Consolidated Holdings | 13 | not reported | (907)* | 259.1M | 0.0 quarters | 10-KDec 31, 2024 |
| Decoy Therapeutics | 8,289 | 228 | (2,652)* | 655,185 | 3.1 quarters | 10-QJun 30, 2026 |
| Nomad Power Solutions | 12,670 | not reported | (1,612)* | 16.1M | 7.9 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.